TRULIEVE CANNABIS

Trulieve reported adjusted Q2 earnings of $0.11 per share versus the consensus estimate of $0.08, while revenue of $271 million was just below the expected $272.21 million. Gross margin was 60% and adjusted EBITDA margin 36%; operations generated $53 million in operating cash flow and $32 million in free cash flow. A one‑time effect from the deconsolidation of Harvest caused a GAAP net loss of $406 million; on an adjusted basis Trulieve posted net income of $20 million. The company ended the quarter with $325 million in cash and $289 million in debt (net cash $36 million) and lowered its full‑year forecast for operating cash flow to at least $225 million while increasing CAPEX to $95 million. In premarket trading the stock was at $8.91, about 1% below the prior close. » More on de.investing.com

Trulieve Cannabis stock climbed premarket after the company released its Q2 2026 results. It is the first full reporting period since medical cannabis was downgraded from Schedule I to Schedule III, removing the burden of Section 280E. Analyst consensus expects about $0.08 earnings per share on roughly $272 million in revenue; management will explain the results on a conference call at 8:30 a.m. ET. Institutional interest has increased since the NYSE uplisting, and seven analysts recommend buying ahead of the release. » More on de.investing.com

Kim Rivers sold 136,811 direct shares for about $1.2 million on June 26, 2026, the final tranche of several sales executed between June 17 and June 26. Rivers retains significant indirect voting power via Traunch IV LLC, suggesting continued alignment with the company. The sale follows a roughly 148% one-year share gain and recent operational momentum, including Q1 revenue strength, positive net income and cash generation, and approval to list on the New York Stock Exchange after rescheduling to Schedule III. » More on finance.yahoo.com